Coya Therapeutics (COYA) Net Income towards Common Stockholders (2022 - 2026)

Coya Therapeutics (COYA) has 5 years of Net Income towards Common Stockholders data on file, last reported at -$7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 1.37% year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at -$26.7 million (up 13.13% YoY), and the FY2025 full-year result was -$21.3 million, down 42.98% from the prior year.
• Net Income towards Common Stockholders climbed to -$7.2 million in Q1 2026, from -$8.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.7 million in Q1 2022 to a low of -$12.2 million in Q4 2024.
• A 5-year average of -$5.3 million and a median of -$4.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders sank 220.46% in 2024 and soared 41.88% in 2025, its largest moves.
• Tracing COYA's Net Income towards Common Stockholders over 5 years: stood at -$3.0 million in 2022, then retreated by 26.85% to -$3.8 million in 2023, then slumped by 220.46% to -$12.2 million in 2024, then grew by 29.82% to -$8.6 million in 2025, then advanced by 15.88% to -$7.2 million in 2026.
• Business Quant data shows COYA's Net Income towards Common Stockholders at -$7.2 million in Q1 2026, -$8.6 million in Q4 2025, and -$4.9 million in Q3 2025.